Navigation Links
DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
Date:9/26/2007

Multinational Trial to Evaluate Safety, Efficacy of Novel Cortisol

Inhibitor

SAN FRANCISCO, Sept. 26 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that it has begun dosing patients in a Phase 2b clinical trial of DIO-902, a novel cortisol synthesis inhibitor being studied for the treatment of type 2 diabetes mellitus (T2DM).

The Phase 2b multinational trial is a randomized, placebo-controlled, double-blinded study designed to evaluate the safety and efficacy of DIO-902 and to determine dosing for pivotal Phase 3 clinical studies. The primary efficacy endpoint being evaluated is the change in HbA1c, a key measurement of glycemic control, compared to placebo. Secondary endpoints include the change in total and LDL-cholesterol, and the change in blood pressure. Top line data from the trial is expected by the second half of 2008.

"The rollout of this multinational, multicenter trial demonstrates DiObex's ability to launch a major clinical program for the treatment of metabolic disease," CEO David Cory said. "With treatments for both type 1 and type 2 diabetes in mid-stage clinical study and additional indications under evaluation for DIO-902, DiObex is well positioned to move a strong pipeline of product candidates into the advanced stages of development."

The trial is being conducted at 20 centers across the United States, Australia and New Zealand. Approximately 200 patients will be treated for 16 weeks. Patients who are already on a stable dose of metformin will be randomized to receive placebo or one of three doses of DIO-902 once daily for 16 weeks, with the option of continuing on an open label extension for an additional six months of treatment.

Preclinical and clinical studies have suggested that a link exists between high cortisol levels and visceral adiposity, insulin resistance
'/>"/>

SOURCE DiObex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
2. Diobex Announces Successful Completion of Phase 2a Trial Of DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015  Novartis Pharmaceuticals Corporation (NPC) has been named the ... row on the annual DiversityInc Top 50 Companies for Diversity ... Companies for Diversity on April 23 at an awards ceremony ... ranked second on the DiversityInc Top 10 Companies for Recruitment ... Resource Groups list. David Epstein , ...
(Date:4/24/2015)... 2015  Lannett Company, Inc. (NYSE: LCI ) ... five-year revolving credit facility to $120 million from $50 ... will allow the company to increase borrowings by a ... to securing additional commitments from existing lenders or new ... remains December 18, 2018.   "The amended ...
(Date:4/24/2015)... 24, 2015  Elekta has CE marked the latest ... system , enabling European clinics to deliver a sophisticated ... including advanced 3D planning, IMRT, VMAT and stereotactic planning ... Monaco ® v5.10 provides ... efficiency. Advancements in 3D planning as well as the ...
Breaking Medicine Technology:Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 2Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 3Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 4Lannett Expands Revolving Credit Facility To $120 Million 2Elekta CE marks for Monaco v5.10 treatment planning system 2
(Date:4/26/2015)... 2015 In an article published last ... the head-neck biomechanics occurring during the use of handheld electronic ... to determine that use of a tablet increases mechanical demand ... times - more than when the neck is in a ... study, but pointing out the potential hazards of overuse of ...
(Date:4/25/2015)... 26, 2015 Diversified Communications has ... healthcare event. The Integrative Healthcare Symposium Canada, as ... 2015 at the Sheraton Parkway Toronto North in ... one of the most anticipated events of the ... CME program. The event aims to gather multi-disciplined ...
(Date:4/25/2015)... 2015 The federal multidistrict litigation ... filed against C.R. Bard, Inc. continues to move ... of West Virginia. According to a Pretrial Order ... that day, after certain defendants submitted amended responses ... Order directed that any Preliminary Motions referenced during ...
(Date:4/25/2015)... Gardant Management Solutions will lead sessions ... and sales and marketing at the LeadingAge Illinois ... held from April 29 through May 1 in ... eldercare association in Illinois. The statewide association represents ... including senior housing, assisted living and supportive living ...
(Date:4/25/2015)... 2015 For thirteen years, the Twin Cities ... education event in the nation! This year, on May 5th, ... US to take DI Day on the road by supporting ... CLU, ChFC, RHU, DIA, CLTC, Chief Executive Officer at Secura ... on the change by stating, "The first Twin Cities DI ...
Breaking Medicine News(10 mins):Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4Health News:Integrative Healthcare Event launching in Canada 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:Gardant Management Solutions Staff Shares Operational Expertise 2Health News:Secura Consultants Takes DI Day On The Road 2
... (May 14, 2008) SAGE, the worlds fifth ... in medical publishing with the acquisition of the ... Journal of the Renin-Angiotensin-Aldosterone System. , Published six ... & Vascular Disease (BJDVD) explores the relationship between ...
... WASHINGTON, May 19 It,s important to choose,foods wisely in ... Food,and Drug Administration (FDA) offers help. And it,s right on ... has, for many, become a,regular part of shopping. If you ... thing you look for. Calories per serving is,easy to understand. ...
... NEW YORK, May 19 WebMD Health Corp. (Nasdaq:,WBMD) ... that executives,of WebMD are scheduled to participate at the ... 2008 at 11:45 a.m. ET., Investors, analysts and ... audio broadcast of the presentation over the Internet. The ...
... CITY, May 19 The Arena Football,League (AFL) has ... the lives of children at children,s hospitals throughout the ... 9 of the 2008 regular season,as AFL Children,s Miracle ... Network Celebration is to,generate awareness and raise funds for ...
... has long been known that prolonged exposure to the ... deadliest form of skin cancer. An unanswered question, however, ... melanoma than others. Despite years of research and clinical ... According to the National Cancer Institute, the percentage of ...
... herb used in traditional medicine by many Middle Eastern ... one of the most difficult cancers to treat. Researchers ... found that thymoquinone, an extract of nigella sativa seed ... cells by enhancing the process of programmed cell death. ...
Cached Medicine News:Health News:SAGE acquires 2 new medical journals 2Health News:%DV: Adding Up a Balanced Diet 2Health News:Children's Miracle Network and Arena Football League Partner for First Nationwide Celebration Event 2Health News:Researchers close in on new melanoma gene 2Health News:Traditional herbal medicine kills pancreatic cancer cells, Jefferson researchers report 2
Flattened 13 mm "Graefe type" hook, with 1.5 mm oval hole. Flat serrated handle with polished finish. Overall length: 5.6 inches....
Blunt, fine curved shaft hook to unroll membranes. 24 gauge shaft with dark finish for reduced glare....
0.2 mm Sinskey hook with shaft angled 45 degrees, 10 mm from tip to bend. Flat smooth handle with polished finish. Overall length: 4.6 inches....
2.0 mm cup. Angled 45 degree shaft 8 mm from tip to bend with flat handle and polished finish. Overall length: 4.8 inches....
Medicine Products: